Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Vicarious Surgical Inc. (RBOT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RBOT (1-star) is a SELL. SELL since 1 days. Profits (-23.25%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.25% | Avg. Invested days 28 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 44.25M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 3 | Beta 1.43 | 52 Weeks Range 5.00 - 19.00 | Updated Date 08/15/2025 |
52 Weeks Range 5.00 - 19.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.07 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.14 | Actual -2.23 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -57.73% | Return on Equity (TTM) -125.63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 33488950 | Price to Sales(TTM) - |
Enterprise Value 33488950 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.41 | Shares Outstanding 5278180 | Shares Floating 3116059 |
Shares Outstanding 5278180 | Shares Floating 3116059 | ||
Percent Insiders 22.76 | Percent Institutions 33.88 |
Upturn AI SWOT
Vicarious Surgical Inc.
Company Overview
History and Background
Vicarious Surgical Inc. was founded in 2014. It focuses on developing miniaturized surgical robots to enhance minimally invasive surgery. It went public via SPAC merger in 2021.
Core Business Areas
- Surgical Robotics: Development and commercialization of a surgical robotic system that combines human-like dexterity and 3D visualization within the human body.
Leadership and Structure
The leadership team includes Adam Sachs (CEO). The company has a board of directors and operates with functional departments like R&D, engineering, and commercial operations.
Top Products and Market Share
Key Offerings
- Vicarious Surgical Robot: A surgical robot designed for minimally invasive procedures. Currently, it is in the development and pre-commercialization phase. Market share data is not yet applicable due to being pre-commercialization. Competitors include Intuitive Surgical (ISRG), Medtronic (MDT), and Stryker (SYK).
Market Dynamics
Industry Overview
The surgical robotics market is experiencing significant growth, driven by increasing demand for minimally invasive procedures and technological advancements.
Positioning
Vicarious Surgical aims to differentiate itself with its unique approach to miniaturization and enhanced visualization. This helps them compete with established market leaders.
Total Addressable Market (TAM)
The TAM for minimally invasive surgical procedures is estimated to be in the tens of billions of dollars. Vicarious Surgical is positioned to capture a share of this market as its technology matures.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Strong intellectual property portfolio
- Experienced management team
- Potential for improved surgical outcomes
Weaknesses
- Pre-commercialization stage
- High R&D costs
- Reliance on regulatory approvals
- Limited market presence
Opportunities
- Expanding surgical applications
- Partnerships with hospitals and surgeons
- Global market expansion
- Technological advancements in robotics and visualization
Threats
- Competition from established players
- Technological obsolescence
- Regulatory hurdles
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- ISRG
- MDT
- SYK
Competitive Landscape
Vicarious Surgical faces intense competition from established players with significant resources and market presence. Its advantage lies in its innovative technology and potential to improve surgical outcomes. Its disadvantage lies in its pre-commercial status and need to obtain regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable, as they have no commercial product, growth is currently based on R&D and regulatory advancement
Future Projections: Future growth is contingent upon successful regulatory approvals and commercialization of their robotic system. Analyst estimates vary widely depending on the perceived success of these milestones.
Recent Initiatives: Recent initiatives include continued development and testing of their surgical robot, progress towards regulatory submissions, and building relationships with key opinion leaders in the surgical community.
Summary
Vicarious Surgical is a pre-commercial stage surgical robotics company with innovative technology. Its strengths lie in its miniaturized robot and strong intellectual property. However, it faces challenges in competing with established players, obtaining regulatory approvals, and managing high R&D costs. Success depends on achieving commercialization and capturing market share in the competitive surgical robotics market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vicarious Surgical Inc.
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 2020-09-04 | CEO & Director Mr. Stephen From | ||
Sector Healthcare | Industry Medical Devices | Full time employees 123 | |
Full time employees 123 | |||
Vicarious Surgical Inc. develops and sells single-port surgical robot in the United States. It offers Vicarious Surgical System, a single-port surgical robot that virtually transports surgeons inside the patient to perform invasive surgery. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.